Advanced search
Publication Cover
Future Cardiology Volume 7, 2011 - Issue 2
Submit an article Journal homepage
104
Views
0
CrossRef citations to date
0
Altmetric
Review

Delayed and Indirect Effects of Antiarrhythmic Drugs in Reducing Sudden Cardiac Death

Saurabh Malhotra1 Krannert Institute of Cardiology Indiana University School of MedicineIndianapolisINUSA
&
Mithilesh K Das1 Krannert Institute of Cardiology Indiana University School of MedicineIndianapolisINUSACorrespondence[email protected]
Pages 203-217 | Published online: 31 Mar 2011

Bibliography

  • Mehra R : Global public health problem of sudden cardiac death.J. Electrocardiol., 40(Suppl. 6), S118–S122 (2007).
  • Myerburg RJ , InterianA Jr, Mitrani RM, Kessler KM, Castellanos A: Frequency of sudden cardiac death and profiles of risk. Am. J. Cardiol., 80(5B), 10F–19F (1997).
  • Myerburg RJ , KesslerKM, CastellanosA: Sudden cardiac death: epidemiology, transient risk, and intervention assessment.Ann. Intern. Med., 119(12), 1187–1197 (1993).
  • Huikuri HV , CastellanosA, MyerburgRJ: Sudden death due to cardiac arrhythmias.N. Engl. J. Med., 345(20), 1473–1482 (2001).
  • Zipes DP : Epidemiology and mechanisms of sudden cardiac death.Can. J. Cardiol., 21(Suppl. A), 37–40 (2005).
  • Martinez-Sanchez J , Garcia-AlberolaA, Sanchez-MunozJJ, Penafiel-VerduP, Giner-CaroJA, Valdes-ChavarriM: ICD proarrhythmia as a consequence of an interaction with an algorithm to prevent atrial arrhythmias.Pacing Clin. Electrophysiol., 32(8), 1096–1098 (2009).
  • Lee JC , EpsteinLM, HufferLL, StevensonWG, KoplanBA, TedrowUB: ICD lead proarrhythmia cured by lead extraction.Heart Rhythm, 6(5), 613–618 (2009).
  • Healy E , GoyalS, BrowningCet al.: Inappropriate ICD therapy due to proarrhythmic ICD shocks and hyperpolarization.Pacing Clin. Electrophysiol., 27(3), 415–416 (2004).
  • The Sicilian gambit. A new approach to the classification of antiarrhythmic drugs based on their actions on arrhythmogenic mechanisms. Task force of the working group on arrhythmias of the European Society of Cardiology. Circulation, 84(4), 1831–1851 (1991).
  • Ruberman W , WeinblattE, GoldbergJD, FrankCW, ShapiroS: Ventricular premature beats and mortality after myocardial infarction.N. Engl. J. Med., 297(14), 750–757 (1977).
  • Maggioni AP , ZuanettiG, FranzosiMGet al.: Prevalence and prognostic significance of ventricular arrhythmias after acute myocardial infarction in the fibrinolytic era. GISSI-2 results.Circulation, 87(2), 312–322 (1993).
  • Mukharji J , RudeRE, PooleWKet al.: Risk factors for sudden death after acute myocardial infarction: two-year follow-up.Am. J. Cardiol., 54(1), 31–36 (1984).
  • Preliminary report: Effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. The Cardiac Arrhythmia Suppression Trial (CAST) investigators. N. Engl. J. Med., 321(6), 406–412 (1989).
  • Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. The Cardiac Arrhythmia Suppression Trial II investigators. N. Engl. J. Med., 327(4), 227–233 (1992).
  • Kuck KH , CappatoR, SiebelsJ, RuppelR: Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest: the Cardiac Arrest Study Hamburg (CASH).Circulation, 102(7), 748–754 (2000).
  • McAlister FA , TeoKK: Antiarrhythmic therapies for the prevention of sudden cardiac death.Drugs, 54(2), 235–252 (1997).
  • Zipes DP , CammAJ, BorggrefeMet al.: ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (writing committee to develop guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society.Circulation, 114(10), e385–e484 (2006).
  • Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet, 353(9169), 2001–2007 (1999).
  • The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet, 353(9146), 9–13 (1999).
  • Packer M , CoatsAJ, FowlerMBet al.: Effect of carvedilol on survival in severe chronic heart failure.N. Engl. J. Med., 344(22), 1651–1658 (2001).
  • Dargie HJ : Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial.Lancet, 357(9266), 1385–1390 (2001).
  • Shimizu W : Arrhythmias originating from the right ventricular outflow tract: how to distinguish ‘malignant‘ from ‘benign‘?Heart Rhythm, 6(10), 1507–1511 (2009).
  • Collura CA , JohnsonJN, MoirC, AckermanMJ: Left cardiac sympathetic denervation for the treatment of long QT syndrome and catecholaminergic polymorphic ventricular tachycardia using video-assisted thoracic surgery.Heart Rhythm, 6(6), 752–759 (2009).
  • Julian DG , PrescottRJ, JacksonFS, SzekelyP: Controlled trial of sotalol for one year after myocardial infarction.Lancet, 1(8282), 1142–1147 (1982).
  • Waldo AL , CammAJ, DeruyterHet al.: Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD investigators. Survival with oral d-sotalol.Lancet, 348(9019), 7–12 (1996).
  • Pacifico A , HohnloserSH, WilliamsJHet al.: Prevention of implantable-defibrillator shocks by treatment with sotalol. D, l-sotalol implantable cardioverter-defibrillator study group.N. Engl. J. Med., 340(24), 1855–1862 (1999).
  • Julian DG , CammAJ, FranginGet al.: Randomized trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: emiat. European Myocardial Infarct Amiodarone Trial investigators.Lancet, 349(9053), 667–674 (1997).
  • Malik M , CammAJ: Amiodarone after myocardial infarction: EMIAT and CAMIAT trials.Lancet, 349(9067), 1767–1768 (1997).
  • Cairns JA , ConnollySJ, GentM, RobertsR: Post-myocardial infarction mortality in patients with ventricular premature depolarizations. Canadian amiodarone myocardial infarction arrhythmia trial pilot study.Circulation, 84(2), 550–557 (1991).
  • Doval HC , NulDR, GrancelliHO, PerroneSV, BortmanGR, CurielR: Randomized trial of low-dose amiodarone in severe congestive heart failure. Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina (GESICA).Lancet, 344(8921), 493–498 (1994).
  • Piccini JP , BergerJS, O‘ConnorCM: Amiodarone for the prevention of sudden cardiac death: a meta-analysis of randomized controlled trials.Eur. Heart J., 30(10), 1245–1253 (2009).
  • Bardy GH , LeeKL, MarkDBet al.: Amiodarone or an implantable cardioverter–defibrillator for congestive heart failure.N. Engl. J. Med., 352(3), 225–237 (2005).
  • Kober L , Bloch-ThomsenPE, MollerMet al.: Effect of dofetilide in patients with recent myocardial infarction and left-ventricular dysfunction: a randomised trial.Lancet, 356(9247), 2052–2058 (2000).
  • Torp-Pedersen C , MollerM, Bloch-ThomsenPEet al.: Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide study group.N. Engl. J. Med., 341(12), 857–865 (1999).
  • Brendorp B , ElmingH, JunLet al.: QTc interval as a guide to select those patients with congestive heart failure and reduced left ventricular systolic function who will benefit from antiarrhythmic treatment with dofetilide.Circulation, 103(10), 1422–1427 (2001).
  • Hohnloser SH , CrijnsHJet al., Van Eickels M : Effect of dronedarone on cardiovascular events in atrial fibrillation. N. Engl. J. Med., 360(7), 668–678 (2009).
  • Kober L , Torp-PedersenC, McmurrayJJet al.: Increased mortality after dronedarone therapy for severe heart failure.N. Engl. J. Med., 358(25), 2678–2687 (2008).
  • Camm AJ , PrattCM, SchwartzPJet al.: Mortality in patients after a recent myocardial infarction: a randomized, placebo-controlled trial of azimilide using heart rate variability for risk stratification.Circulation, 109(8), 990–996 (2004).
  • Mitchell LB : Role of drug therapy for sustained ventricular tachyarrhythmias.Cardiol. Clin., 26(3), 405–418, vi (2008).
  • Gavras I , GavrasH: The antiarrhythmic potential of angiotensin II antagonism: experience with losartan.Am. J. Hypertens., 13, 512–517 (2000).
  • Minisi A , ThamesM: Distribution of left ventricular sympathetic afferents demonstrated by reflex responses to transmural myocardial ischemia and to intracoronary and epicardial bradykinin.Circulation, 87(1), 240–246 (1993).
  • Alberte C , ZipesDP: Use of nonantiarrhythmic drugs for prevention of sudden cardiac death.J. Cardiovasc. Electrophysiol., 14(Suppl. 9), S87–S95 (2003).
  • Pogwizd S : Focal mechanisms underlying ventricular tachycardia during prolonged ischemic cardiomyopathy.Circulation, 90(3), 1441–1458 (1994).
  • Yusuf S , SleightP, PogueJ, BoschJ, DaviesR, DagenaisG: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation study investigators.N. Engl. J. Med., 342(3), 145–153 (2000).
  • Domanski MJ , ExnerDV, BorkowfCB, GellerNL, RosenbergY, PfefferMA: Effect of angiotensin converting enzyme inhibition on sudden cardiac death in patients following acute myocardial infarction. A meta-analysis of randomized clinical trials.J. Am. Coll. Cardiol., 33(3), 598–604 (1999).
  • Garg R , YusufS: Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative group on ACE inhibitor trials.JAMA, 273(18), 1450–1456 (1995).
  • Dickstein K , KjekshusJ: Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAL randomized trial. Optimal trial in myocardial infarction with angiotensin II antagonist losartan.Lancet, 360(9335), 752–760 (2002).
  • Jong P , DemersC, MckelvieRS, LiuPP: Angiotensin receptor blockers in heart failure: meta-analysis of randomized controlled trials.J. Am. Coll. Cardiol., 39(3), 463–470 (2002).
  • Pitt B , ZannadF, RemmeWJet al.: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators.N. Engl. J. Med., 341(10), 709–717 (1999).
  • Pitt B , RemmeW, ZannadFet al.: Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.N. Engl. J. Med., 348(14), 1309–1321 (2003).
  • Shanes JG , MinadeoKN, MoretA, GronerM, TabaieSA: Statin therapy in heart failure: prognostic effects and potential mechanisms.Am. Heart J., 154(4), 617–623 (2007).
  • Vyas A , GuoH, MossAet al.: Reduction in ventricular tachyarrhythmias with statins in the Multicenter Automatic Defibrillator Implantation Trial (MADIT)-II.J. Am. Coll. Cardiol., 47(4), 769–773 (2006).
  • Goldberger JJ , SubaciusH, SchaechterAet al.: Effects of statin therapy on arrhythmic events and survival in patients with nonischemic dilated cardiomyopathy.J. Am. Coll. Cardiol., 48(6), 1228–1233 (2006).
  • Kjekshus J , ApetreiE, BarriosVet al.: Rosuvastatin in older patients with systolic heart failure.N. Engl. J. Med., 357(22), 2248–2261 (2007).
  • Tavazzi L , MaggioniAP, MarchioliRet al.: Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomized, double-blind, placebo-controlled trial.Lancet, 372(9645), 1231–1239 (2008).
  • Leaf A , KangJX, XiaoYF: Fish oil fatty acids as cardiovascular drugs.Curr. Vasc. Pharmacol., 6(1), 1–12 (2008).
  • Albert CM , OhK, WhangWet al.: Dietary α-linolenic acid intake and risk of sudden cardiac death and coronary heart disease.Circulation, 112(21), 3232–3238 (2005).
  • Marchioli R , BarziF, BombaEet al.: Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell‘Infarto Miocardico (GISSI)-Prevenzione.Circulation, 105(16), 1897–1903 (2002).
  • Macchia A , LevantesiG, FranzosiMGet al.: Left ventricular systolic dysfunction, total mortality, and sudden death in patients with myocardial infarction treated with n-3 polyunsaturated fatty acids.Eur. J. Heart Fail., 7(5), 904–909 (2005).
  • Brouwer I , ZockP, CammAet al.: Effect of fish oil on ventricular tachyarrhythmia and death inpatients with implantable cardioverter defibrillators.J. Am. Coll. Cardiol., 295(22), 2613–2619 (2006).
  • Brouwer IA , ZockPL, CammAJet al.: Effect of fish oil on ventricular tachyarrhythmia and death in patients with implantable cardioverter defibrillators: the Study on Omega-3 Fatty Acids and Ventricular Arrhythmia (SOFA) randomized trial.JAMA, 295(22), 2613–2619 (2006).
  • Brouwer IA , RaittMH, DullemeijerCet al.: Effect of fish oil on ventricular tachyarrhythmia in three studies in patients with implantable cardioverter defibrillators.Eur. Heart J., 30(7), 820–826 (2009).
  • Tavazzi L , MaggioniAP, MarchioliRet al.: Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial.Lancet, 372(9645), 1223–1230 (2008).
  • Echt DS , LiebsonPR, MitchellLBet al.: Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The cardiac arrhythmia suppression trial.N. Engl. J. Med., 324(12), 781–788 (1991).
  • Moss AJ , HallWJ, CannomDSet al.: Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter automatic defibrillator implantation trial investigators.N. Engl. J. Med., 335(26), 1933–1940 (1996).
  • Moss AJ , ZarebaW, HallWJet al.: Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.N. Engl. J. Med., 346(12), 877–883 (2002).
  • Buxton AE , LeeKL, FisherJD, JosephsonME, PrystowskyEN, HafleyG: A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter unsustained tachycardia trial investigators.N. Engl. J. Med., 341(25), 1882–1890 (1999).
  • Bristow MR , SaxonLA, BoehmerJet al.: Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.N. Engl. J. Med., 350(21), 2140–2150 (2004).
  • Cleland JG , DaubertJC, ErdmannEet al.: The effect of cardiac resynchronization on morbidity and mortality in heart failure.N. Engl. J. Med., 352(15), 1539–1549 (2005).
  • A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. The Antiarrhythmics Versus Implantable Defibrillators (AVID) investigators. N. Engl. J. Med., 337(22), 1576–1583 (1997).
  • Connolly SJ , GentM, RobertsRSet al.: Canadian Implantable Defibrillator Study (CIDS): a randomized trial of the implantable cardioverter defibrillator against amiodarone.Circulation, 101(11), 1297–1302 (2000).
  • Nademanee K , VeerakulG, MowerMet al.: Defibrillator Versus β-Blockers for Unexplained Death in Thailand (DEBUT): a randomized clinical trial.Circulation, 107(17), 2221–2226 (2003).
  • Lau EW , GriffithMJ, PathmanathanRKet al.: The Midlands trial of empirical Amiodarone Versus Electrophysiology-guided interventions and implantable cardioverter-defibrillators (MAVERIC): a multi-centre prospective randomised clinical trial on the secondary prevention of sudden cardiac death.Europace, 6(4), 257–266 (2004).
  • Zareba W , MossAJ, DaubertJP, HallWJ, RobinsonJL, AndrewsM: Implantable cardioverter defibrillator in high-risk long QT syndrome patients.J. Cardiovasc. Electrophysiol., 14(4), 337–341 (2003).
  • Goldenberg I , BradleyJ, MossAet al.: β-blocker efficacy in high-risk patients with the congenital long-QT syndrome types 1 and 2: implications for patient management.J. Cardiovasc. Electrophysiol. doi: 10.1111/j.1540-8167.2010.01737.x (2010) (Epub ahdead of print).
  • Schwartz PJ , PrioriSG, LocatiEHet al.: Long QT syndrome patients with mutations of the scn5a and herg genes have differential responses to Na+ channel blockade and to increases in heart rate. Implications for gene-specific therapy.Circulation, 92(12), 3381–3386 (1995).
  • Shimizu W , AibaT, AntzelevitchC: Specific therapy based on the genotype and cellular mechanism in inherited cardiac arrhythmias. Long QT syndrome and Brugada syndrome.Curr. Pharm. Des., 11(12), 1561–1572 (2005).
  • Moss AJ , ZarebaW, SchwarzKQ, RoseroS, McNittS, RobinsonJL: Ranolazine shortens repolarization in patients with sustained inward sodium current due to type-3 long-QT syndrome.J. Cardiovasc. Electrophysiol., 19(12), 1289–1293 (2008).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.